Business Context and Reporting Period
Company: Halozyme Therapeutics, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Industry: Biopharmaceutical (Recombinant human enzymes/hyaluronidases)
Halozyme develops and commercializes recombinant human enzymes, primarily rHuPH20, to facilitate drug delivery or correct diseased tissue. The company operates through proprietary programs (Ultrafast Insulin, PEGPH20) and strategic partnerships with Roche and Baxter. Key marketed products include HYLENEX (recalled in May 2010 due to manufacturing non-compliance) and Cumulase (IVF). In January 2011, the company mutually terminated its HYLENEX partnership with Baxter, reacquiring worldwide marketing rights.
Key Financial Metrics (Year Ended Dec 31, 2010)
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenues | $13.6 million | $13.7 million |
| Net Loss | $(53.2) million | $(58.4) million |
| Net Loss Per Share (Basic/Diluted) | $(0.56) | $(0.67) |
| Cash and Cash Equivalents | $83.3 million | $67.5 million |
| Working Capital | $74.2 million | $60.0 million |
| Accumulated Deficit | $(225.3) million | $(172.0) million |
| Deferred Revenue | $58.1 million | $60.5 million |
Revenue Composition: Product sales were $0.9 million (down 8% from 2009). Revenues from collaborative agreements were $12.7 million, driven by amortization of license fees and milestone payments from Roche and Baxter.
Expenses: Research and Development (R&D) expenses were $51.8 million (down 8% from 2009). Selling, General, and Administrative (SG&A) expenses were $15.1 million.
Material Changes vs. Prior Period
- Partnership Termination: The HYLENEX partnership with Baxter was terminated effective January 7, 2011. This resulted in a $0.9 million reserve for inventory obsolescence and a recharacterization of $1.0 million in deferred revenue as a reserve for product returns.
- Leadership Change: On December 2, 2010, Jonathan E. Lim, M.D., resigned as CEO. Gregory I. Frost, Ph.D., was appointed President and CEO.
- Workforce Reduction: A corporate reorganization in October 2010 reduced the workforce by approximately 25%, primarily in discovery research and preclinical areas, resulting in $1.3 million in severance costs.
- Capital Raise: In September 2010, the company raised approximately $60.2 million through an underwritten public offering of common stock.
- Patent Status: U.S. Patent No. 7,767,429 was issued in August 2010 (expires 2027). An opposition to the European counterpart patent was filed in August 2010.
Guidance, Outlook, and Risks
Outlook: Management anticipates a net cash burn of $47.0 to $52.0 million for 2011. The company expects to fund operations for at least the next 12 months with existing cash ($83.3 million) and anticipated revenues. Future funding may require additional equity or debt financing.
Product Pipeline & Milestones:
- HYLENEX: Expected reintroduction in the second half of 2011, pending FDA approval of remediation plans.
- Roche Partnership: Phase 3 trials for subcutaneous Herceptin (enrollment completed Dec 2010) and MabThera (started Feb 2011). Regulatory filing for Herceptin expected in 2012.
- Baxter Partnership (Gammagard): Phase 3 trial for HyQ completed Jan 2011; regulatory filing expected in 2011.
- Ultrafast Insulin: Phase 2 trials completed; Phase 1 pump study initiated Jan 2011.
Key Risks:
- Regulatory Approval: No proprietary or partnered products are currently in the regulatory approval process; delays or failures would impair revenue generation.
- Manufacturing: Reliance on contract manufacturers (Avid, Cook) for API; scale-up risks for Roche obligations.
- Profitability: History of net losses since inception; no assurance of future profitability.
- Intellectual Property: Ongoing opposition to European patent; uncertainty regarding patent scope and enforceability.
Investor Verification Checklist
- HYLENEX Reintroduction Timeline: Verify the status of FDA communications and the likelihood of a second-half 2011 relaunch.
- Deferred Revenue Amortization: Confirm the new amortization schedule for the $7.8 million upfront payment and $9.3 million product-based payments from the terminated Baxter HYLENEX partnership.
- Cash Burn Rate: Monitor quarterly cash usage against the projected $47M-$52M burn rate for 2011.
- Roche Milestone Payments: Track progress of Phase 3 trials for subcutaneous Herceptin and MabThera to assess potential future milestone revenue.
- European Patent Opposition: Review the outcome of the opposition filed against European Patent EP1603541.